To further confirm that activated FASN and the suppressed phospho-AMPKThr172 due to high ATP production are responsible for enhancing ovarian cancer oncogenic properties in OCM, we added two potent FASN-specific inhibitors (orlistat and GSK2194069 (GSK)) or an AMPK potent activator (PF-06409577 (PF)) to ovarian cancer cells in OCM. This evidence concerns the gene PRKAA1 and ovarian cancer.